JMP Securities Initiates Coverage on Cogentix Medical Inc (NASDAQ:CGNT). What May be Next?

December 8, 2017 - By Michael Collier

 JMP Securities Initiates Coverage on Cogentix Medical Inc (NASDAQ:CGNT). What May be Next?

Why Has JMP Securities Given Cogentix Medical Inc (NASDAQ:CGNT) a $5.0 Price Target

JMP Securities analyst started coverage on Cogentix Medical Inc (NASDAQ:CGNT) with a $5.0 target price per share and “Buy” rating. The target price per share indicates a potential upside of 69.49 % from firm’s last stock close.

Cogentix Medical, Inc. (NASDAQ:CGNT) Ratings Coverage

Among 4 analysts covering Cogentix Medical (NASDAQ:CGNT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cogentix Medical has $5.0 highest and $1.15 lowest target. $4.19’s average target is 42.03% above currents $2.95 stock price. Cogentix Medical had 8 analyst reports since November 5, 2015 according to SRatingsIntel. The rating was maintained by Roth Capital on Wednesday, August 2 with “Buy”. The firm has “Neutral” rating by Roth Capital given on Friday, May 6. On Tuesday, July 18 the stock rating was maintained by Roth Capital with “Buy”. JMP Securities initiated the shares of CGNT in report on Friday, October 6 with “Buy” rating. The company was maintained on Wednesday, November 8 by Roth Capital. The stock of Cogentix Medical, Inc. (NASDAQ:CGNT) earned “Buy” rating by TH Capital on Thursday, November 5. The company was upgraded on Thursday, November 5 by Roth Capital.

The stock increased 3.87% or $0.11 during the last trading session, reaching $2.95. About 56,555 shares traded. Cogentix Medical, Inc. (NASDAQ:CGNT) has risen 83.33% since December 8, 2016 and is uptrending. It has outperformed by 66.63% the S&P500.

Cogentix Medical, Inc., a medical device company, designs, develops, makes, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company has market cap of $179.67 million. The firm offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. It currently has negative earnings. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes.

More notable recent Cogentix Medical, Inc. (NASDAQ:CGNT) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on December 01, 2017, also Prnewswire.com with their article: “Cogentix Medical Announces Palmetto GBA Extends Medicare Coverage on UrgentĀ® PC” published on December 06, 2017, Prnewswire.com published: “Cogentix Medical Announces Cahaba GBA, LLC Extends Coverage for Urgent PC …” on September 13, 2017. More interesting news about Cogentix Medical, Inc. (NASDAQ:CGNT) were released by: Prnewswire.com and their article: “Cogentix Medical Acquires Genesis Medical; Transaction to Further Increase …” published on July 26, 2017 as well as Seekingalpha.com‘s news article titled: “A Technical Analysis Of Cogentix Medical: Poised To Break Out” with publication date: December 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.